[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 63 of about 63
1. Schillaci G, De Socio GV, Pucci G, Mannarino MR, Helou J, Pirro M, Mannarino E: Aortic stiffness in untreated adult patients with human immunodeficiency virus infection. Hypertension; 2008 Aug;52(2):308-13
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aortic stiffness in untreated adult patients with human immunodeficiency virus infection.
  • In 39 untreated HIV-infected patients and 78 individually matched age-, sex-, and blood pressure-matched HIV-uninfected control subjects, we determined aortic pulse wave velocity (PWV), a direct noninvasive measure of aortic stiffness, by tonometric method.
  • [MeSH-minor] Adult. Case-Control Studies. Female. Follow-Up Studies. Humans. Linear Models. Male. Multivariate Analysis. Pulsatile Flow. Reference Values. Risk Factors. Severity of Illness Index. Vascular Resistance / physiology

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18559718.001).
  • [ISSN] 1524-4563
  • [Journal-full-title] Hypertension (Dallas, Tex. : 1979)
  • [ISO-abbreviation] Hypertension
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Hensel M, Zoz M, Giesecke C, Benner A, Neben K, Jauch A, Stilgenbauer S, Ho AD, Krämer A: High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B-cell chronic lymphocytic leukemia. Int J Cancer; 2007 Sep 1;121(5):978-83
Genetic Alliance. consumer health - Leukemia, B-cell, chronic.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B-cell chronic lymphocytic leukemia.
  • B-cell chronic lymphocytic leukemia (CLL) is characterized by a high rate of clonal genomic alterations and a low proliferative activity with cell cycle arrest in G(0)/G(1) phase.
  • To investigate whether centrosome aberrations do occur in CLL and whether they correlate with common prognostic factors and disease activity, we examined peripheral blood mononuclear cells (PBMC) from 70 patients with previously untreated CLL using an antibody to gamma-tubulin.
  • Accordingly, more centrosome aberrations were found in PHA-stimulated T lymphocytes from healthy individuals as well as in B cells from surgically removed tonsil tissue of patients with acute tonsillitis as compared to the peripheral blood B lymphocytes from the control group.
  • [MeSH-major] Cell Proliferation. Centrosome. Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Female. Flow Cytometry. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17417785.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Tournis ST, Giannikou PV, Paspati IN, Katsalira EA, Voskaki IC, Lyritis GP: Co-existence of X-linked hypophosphatemic rickets (XLH) and primary hyperparathyroidism: case report and review of the literature. J Musculoskelet Neuronal Interact; 2005 Jun;5(2):150-4
Genetic Alliance. consumer health - Rickets.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of an adult untreated male XLH patient with primary HPT and give a brief review of the literature regarding the prevalence and pathophysiology of this complication.

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • Genetic Alliance. consumer health - Hypophosphatemic rickets.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951631.001).
  • [ISSN] 1108-7161
  • [Journal-full-title] Journal of musculoskeletal & neuronal interactions
  • [ISO-abbreviation] J Musculoskelet Neuronal Interact
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Parathyroid Hormone
  •  go-up   go-down


Advertisement
4. Weber J, Collmann H, Czarnetzki A, Spring A, Pusch CM: Morphometric analysis of untreated adult skulls in syndromic and nonsyndromic craniosynostosis. Neurosurg Rev; 2008 Apr;31(2):179-88
Genetic Alliance. consumer health - Craniosynostosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphometric analysis of untreated adult skulls in syndromic and nonsyndromic craniosynostosis.
  • The aim of this study was to perform a morphometric analysis of untreated adult skulls displaying syndromic and nonsyndromic craniosynostosis.
  • We analyzed, in detail, 42 adult craniosynostoses (18 scaphocephaly, 11 anterior plagiocephaly, 2 trigonocephaly, 9 oxycephaly, and 2 brachycephaly) from archeological (three skulls) and pathoanatomical samples (39 skulls).
  • The mean cranial length in adult scaphocephaly was 12% greater than anatomical skulls.
  • These data on adult craniosynostosis could be of interest for physicians dealing with craniosynostotic children.
  • [MeSH-minor] Adult. Archaeology. Biological Specimen Banks. Cerebrovascular Disorders / pathology. DNA / biosynthesis. DNA / genetics. Humans. Intracranial Hypertension / pathology. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1984 Sep;61(3):557-62 [6747694.001]
  • [Cites] Am J Med Genet. 1993 Oct 1;47(5):581-616 [8266985.001]
  • [Cites] Am J Med Genet A. 2005 Aug 1;136A(4):327-42 [15937945.001]
  • [Cites] Anthropol Anz. 1993 Mar;51(1):1-29 [8476271.001]
  • [Cites] Scand J Plast Reconstr Surg. 1982;16(3):245-53 [7167778.001]
  • [Cites] Mol Biol Evol. 2004 Nov;21(11):2005-11 [15254256.001]
  • [Cites] Neurosurgery. 1996 Oct;39(4):691-9 [8880760.001]
  • [Cites] J Neurosurg Spine. 2004 Sep;1(2):238-42 [15347014.001]
  • [Cites] Eur J Hum Genet. 1999 Jan;7(1):27-33 [10094188.001]
  • [Cites] Cleft Palate Craniofac J. 1994 Sep;31(5):385-96 [7986800.001]
  • [Cites] AJR Am J Roentgenol. 1990 Mar;154(3):658 [2106245.001]
  • [Cites] Anal Biochem. 2000 Sep 10;284(2):408-11 [10964428.001]
  • [Cites] Am J Hum Genet. 1997 Mar;60(3):555-64 [9042914.001]
  • [Cites] J Neurosurg. 2001 Mar;94(3):377-85 [11235939.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Jan;24(1):45-51 [12533326.001]
  • [Cites] J Neurosurg. 1984 Apr;60(4):727-36 [6707742.001]
  • [Cites] Lancet. 1998 Mar 21;351(9106):877-8 [9525367.001]
  • [Cites] Paleopathol Newsl. 1992 Mar;(77):12-15 [11623191.001]
  • [Cites] Lancet. 1997 Apr 12;349(9058):1059-62 [9107244.001]
  • [Cites] Semin Pediatr Neurol. 2002 Dec;9(4):274-91 [12523552.001]
  • [Cites] Am J Hum Genet. 1998 Jun;62(6):1370-80 [9585583.001]
  • [Cites] J Appl Genet. 2003;44(3):269-90 [12923304.001]
  • [Cites] Am J Med Genet. 2002 Jun 15;110(2):136-43 [12116251.001]
  • [Cites] J Craniofac Surg. 1990 Jan;1(1):1-3 [2088558.001]
  • [Cites] Br J Plast Surg. 1992 Jul;45(5):394-7 [1638296.001]
  • [Cites] J Med Genet. 1997 Aug;34(8):683-4 [9279764.001]
  • [Cites] Plast Reconstr Surg. 1992 Sep;90(3):377-81 [1513883.001]
  • [Cites] Mol Biol Evol. 2004 May;21(5):957-64 [15014140.001]
  • [Cites] Acta Neurochir (Wien). 2003 Mar;145(3):233-4 [12632121.001]
  • [Cites] Plast Reconstr Surg. 2001 Nov;108(6):1492-8; discussion 1499-500 [11711916.001]
  • (PMID = 17992550.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 9007-49-2 / DNA
  •  go-up   go-down


5. Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N: Body composition in untreated adult patients with Laron syndrome (primary GH insensitivity). Clin Endocrinol (Oxf); 2006 Jul;65(1):114-7
Genetic Alliance. consumer health - Laron syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body composition in untreated adult patients with Laron syndrome (primary GH insensitivity).
  • OBJECTIVE: To quantify body adiposity and its distribution in untreated adult patients with Laron syndrome (LS; primary GH insensitivity) caused by molecular defects of the GH receptor gene or postreceptor pathways and characterized by dwarfism, obesity, insulin resistance and hyperlipidaemia.
  • [MeSH-minor] Absorptiometry, Photon. Adult. Body Mass Index. Case-Control Studies. Female. Humans. Insulin-Like Growth Factor I / deficiency. Lipids / blood. Male. Middle Aged. Sex Factors. Statistics, Nonparametric

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16817829.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lipids; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


6. Rashtak S, Ettore MW, Homburger HA, Murray JA: Combination testing for antibodies in the diagnosis of coeliac disease: comparison of multiplex immunoassay and ELISA methods. Aliment Pharmacol Ther; 2008 Sep 15;28(6):805-13
MedlinePlus Health Information. consumer health - Celiac Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We compared the sensitivity, specificity and accuracy of MIA and ELISA methods for TTG and DGP antibodies in mainly adult untreated coeliac patients (n = 92) and controls (n = 124).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Dis Sci. 2008 Jun;53(6):1582-8 [17985240.001]
  • [Cites] Scand J Gastroenterol. 2007 Dec;42(12):1428-33 [17852878.001]
  • [Cites] Gastroenterology. 2001 Feb;120(3):636-51 [11179241.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Jun;13(6):635-7 [11434587.001]
  • [Cites] Clin Chem. 2001 Nov;47(11):2023-8 [11673371.001]
  • [Cites] J Clin Pathol. 2002 Jun;55(6):424-8 [12037023.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):219-21 [12590232.001]
  • [Cites] Rom J Gastroenterol. 2003 Jun;12(2):101-6 [12853995.001]
  • [Cites] Pathology. 2003 Aug;35(4):285-304 [12959764.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):2027-33 [14499783.001]
  • [Cites] Clin Immunol. 2004 Mar;110(3):252-66 [15047203.001]
  • [Cites] Dig Dis Sci. 2004 Apr;49(4):546-50 [15185855.001]
  • [Cites] Clin Chem. 2004 Nov;50(11):2125-35 [15388634.001]
  • [Cites] Gastroenterology. 1992 Jan;102(1):330-54 [1727768.001]
  • [Cites] Neth J Med. 1998 Jul;53(1):15-9 [9718937.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):888-94 [10201452.001]
  • [Cites] Clin Chem. 2004 Dec;50(12):2370-5 [15472035.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4 Suppl 1):S52-6 [15825127.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4 Suppl 1):S74-8 [15825130.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Jun;19(3):389-400 [15925844.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2005 Jul;41(1):44-8 [15990629.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Sep;4(9):1112-7 [16860613.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1981-2002 [17087937.001]
  • [Cites] Ann N Y Acad Sci. 2007 Aug;1109:330-7 [17785322.001]
  • [Cites] Clin Exp Immunol. 2007 Nov;150(2):285-93 [17803713.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1731-43 [17960014.001]
  • [Cites] Clin Med Res. 2007 Oct;5(3):184-92 [18056028.001]
  • [Cites] Autoimmunity. 2008 Feb;41(1):116-21 [18176874.001]
  • [Cites] Clin Chem. 2007 Dec;53(12):2186-92 [17901114.001]
  • [Cites] Liver Int. 2008 Apr;28(4):467-76 [18339073.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):426-32; quiz 370 [18304884.001]
  • [Cites] J Clin Gastroenterol. 2008 May-Jun;42(5):460-5 [18344893.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2000 Nov;31(5):513-9 [11144436.001]
  • (PMID = 19145736.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK-057892; United States / NIDDK NIH HHS / DK / DK057892-07; United States / NIDDK NIH HHS / DK / R01 DK057892; United States / NIDDK NIH HHS / DK / R01 DK057892-07; United States / NIDDK NIH HHS / DK / R01 DK057892-08
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Immunoglobulin A; 0 / Immunoglobulin G
  • [Other-IDs] NLM/ NIHMS73354; NLM/ PMC2666354
  •  go-up   go-down


7. Zicha J, Dobesová Z, Kunes J: Late blood pressure reduction in SHR subjected to transient captopril treatment in youth: possible mechanisms. Physiol Res; 2008;57(3):495-8
Hazardous Substances Data Bank. CAPTOPRIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adult untreated SHR aged 30-34 weeks were compared with animals subjected to chronic captopril treatment for 6 weeks either in youth (between 4 and 10 weeks of age) or in adulthood (between 24 and 30 weeks of age).
  • Antihypertensive effects of captopril were more pronounced in young than adult SHR.
  • The magnitude of nifedipine-sensitive component of sympathetic vasoconstriction is decisive for BP maintenance not only in untreated SHR but also in SHR during active captopril treatment by or after its withdrawal.

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • Hazardous Substances Data Bank. Nifedipine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18597587.001).
  • [ISSN] 0862-8408
  • [Journal-full-title] Physiological research
  • [ISO-abbreviation] Physiol Res
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Antihypertensive Agents; 0 / Vasodilator Agents; 9G64RSX1XD / Captopril; I9ZF7L6G2L / Nifedipine
  •  go-up   go-down


8. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N, Marcucci G, Calin GA, Kornblau SM, Kantarjian H, Bloomfield CD, Andreeff M, Croce CM: MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood; 2008 Mar 15;111(6):3183-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.
  • To determine whether miRNAs are associated with cytogenetic abnormalities and clinical features in acute myeloid leukemia (AML), we evaluated the miRNA expression of CD34(+) cells and 122 untreated adult AML cases using a microarray platform.
  • An independent set of 60 untreated AML patients was used to validate the outcome signatures using real-time polymerase chain reaction.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2004 Oct;18(10):1565-8 [15452588.001]
  • [Cites] Oncogene. 2007 Sep 13;26(42):6133-40 [17404574.001]
  • [Cites] Blood. 1999 May 1;93(9):3074-80 [10216104.001]
  • [Cites] N Engl J Med. 1999 Sep 30;341(14):1051-62 [10502596.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1550-7 [15973452.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Cell. 2005 Dec 2;123(5):819-31 [16325577.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18081-6 [16330772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3589-95 [11369655.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):357-64 [12139719.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Cancer Biol Ther. 2003 Mar-Apr;2(2):164-70 [12750556.001]
  • [Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Science. 2004 Apr 23;304(5670):594-6 [15105502.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9740-4 [15210942.001]
  • [Cites] Cell. 2003 Dec 26;115(7):787-98 [14697198.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1169-81 [16564011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5078-83 [16549775.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9 [16641092.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2113-29 [16762633.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11590-3 [17178851.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2750-5 [17293455.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2799-803 [17072344.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1130-4 [17554337.001]
  • [Cites] Blood. 1997 Jan 15;89(2):630-43 [9002967.001]
  • (PMID = 18187662.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA16058; United States / NCI NIH HHS / CA / P01CA76259; United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / P01 CA076259; United States / NCI NIH HHS / CA / P01CA81534; United States / NCI NIH HHS / CA / P30 CA016058; United States / NCI NIH HHS / CA / P01 CA055164
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2265455
  •  go-up   go-down


9. Leathwick DM, Miller CM, Atkinson DS, Haack NA, Waghorn TS, Oliver AM: Managing anthelmintic resistance: untreated adult ewes as a source of unselected parasites, and their role in reducing parasite populations. N Z Vet J; 2008 Aug;56(4):184-95
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Managing anthelmintic resistance: untreated adult ewes as a source of unselected parasites, and their role in reducing parasite populations.
  • AIMS: To test the hypotheses that when untreated adult ewes are rotationally grazed (follow behind) on pastures after lambs receiving routine anthelmintic treatments, the ewes can function as a source of unselected parasites in refugia, capable of slowing the development of anthelmintic resistance, and suppress the build-up of parasites resulting from the development of anthelmintic resistance.
  • METHODS: Firstly, the potential of untreated adult ewes to slow the development of anthelmintic resistance, and to suppress parasite populations under differing levels of anthelmintic efficacy, was investigated using a simulation model.
  • RESULTS: Model simulations indicated that parasites cycling in the untreated ewes could slow the development of resistance being selected for by the anthelmintic treatments given to lambs and this could occur without a nett increase in larval numbers on pasture.
  • In the field trial, untreated adult ewes contributed to pasture infestations of most parasite species, but not Nematodirus spp.
  • CONCLUSIONS: Untreated adult ewes were a source of unselected genotypes, capable of slowing the development of anthelmintic resistance in most, but not all, parasite species.
  • Further, the potential of adult ewes to remove from pasture more parasite larvae than they contribute through faecal contamination indicates a potentially useful role in suppressing parasite populations, particularly when worm control in lambs is less effective as a result of anthelmintic resistance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18690255.001).
  • [ISSN] 0048-0169
  • [Journal-full-title] New Zealand veterinary journal
  • [ISO-abbreviation] N Z Vet J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anthelmintics
  •  go-up   go-down


10. Chen DY, Lan JL, Lin FJ, Hsieh TY: Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still's disease. Clin Rheumatol; 2007 Mar;26(3):393-400
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still's disease.
  • To investigate serum levels of soluble Fas (sFas), soluble Fas ligand (sFas-L), and matrix metalloproteinase-3 (MMP-3) in patients with active untreated adult onset Still's disease (AOSD).
  • Serum levels of sFas, sFas-L, and MMP-3 were determined by enzyme-linked immunosorbent assays in 20 patients with active untreated AOSD, 20 patients with active rheumatoid arthritis (RA), and 20 healthy controls.
  • Significantly higher levels of sFas, sFas-L, and MMP-3 in sera were found in active untreated AOSD patients compared to healthy controls.
  • Serum levels of sFas, sFas-L, and MMP-3 fluctuated and were found to be parallel to disease activity of AOSD. sFas, sFas-L, and MMP-3, which were significantly elevated in sera of active untreated AOSD patients and paralleled disease activity, may be involved in the pathogenesis of this disease.
  • [MeSH-major] Antigens, CD95 / blood. Fas Ligand Protein / blood. Matrix Metalloproteinase 3 / blood. Still's Disease, Adult-Onset / blood
  • [MeSH-minor] Adult. Arthritis, Rheumatoid / blood. Case-Control Studies. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Still's disease adult onset.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Rheumatol. 2003 Nov;30(11):2422-7 [14677188.001]
  • [Cites] Lab Invest. 2003 Dec;83(12):1839-48 [14691302.001]
  • [Cites] Arthritis Rheum. 1998 Jan;41(1):1-9 [9433863.001]
  • [Cites] Nature. 1995 Feb 2;373(6513):444-8 [7530337.001]
  • [Cites] J Rheumatol. 1987 Dec;14(6):1139-46 [3325642.001]
  • [Cites] J Immunol. 1996 Jun 15;156(12):4622-30 [8648105.001]
  • [Cites] Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S2-14 [8811058.001]
  • [Cites] Immunol Today. 1995 Jan;16(1):39-43 [7533498.001]
  • [Cites] Medicine (Baltimore). 1991 Mar;70(2):118-36 [2005777.001]
  • [Cites] Int Immunol. 1994 Oct;6(10):1545-53 [7530039.001]
  • [Cites] Ann Rheum Dis. 1971 Mar;30(2):121-33 [5315135.001]
  • [Cites] Nature. 1992 Mar 26;356(6367):314-7 [1372394.001]
  • [Cites] J Exp Med. 1997 May 19;185(10):1837-49 [9151709.001]
  • [Cites] J Rheumatol. 1992 Mar;19(3):424-30 [1578458.001]
  • [Cites] Ann Rheum Dis. 2004 Oct;63(10):1300-6 [15361391.001]
  • [Cites] J Clin Immunol. 2002 Jul;22(4):220-7 [12148596.001]
  • [Cites] J Rheumatol. 2003 Jan;30(1):10-21 [12508384.001]
  • [Cites] Cell. 1997 Feb 7;88(3):355-65 [9039262.001]
  • [Cites] Science. 1998 Apr 10;280(5361):243-8 [9535647.001]
  • [Cites] Arthritis Rheum. 1997 Jun;40(6):1054-63 [9182916.001]
  • [Cites] Rheumatology (Oxford). 2003 Jan;42(1):83-8 [12509618.001]
  • [Cites] Lupus. 2001;10(4):284-8 [11341105.001]
  • [Cites] Autoimmunity. 2002 Feb;35(1):15-20 [11908702.001]
  • [Cites] J Exp Med. 1995 Dec 1;182(6):1777-83 [7500022.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1449-56 [7533326.001]
  • [Cites] J Rheumatol. 2004 Nov;31(11):2189-98 [15517632.001]
  • [Cites] Arthritis Rheum. 1988 Mar;31(3):315-24 [3358796.001]
  • [Cites] World J Gastroenterol. 2004 Nov 1;10(21):3151-6 [15457562.001]
  • [Cites] Cell. 1993 Dec 17;75(6):1169-78 [7505205.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1341-8 [9028957.001]
  • [Cites] EMBO J. 1995 Mar 15;14(6):1129-35 [7536672.001]
  • [Cites] Science. 1998 Nov 27;282(5394):1714-7 [9831564.001]
  • [Cites] Am J Hematol. 2000 Jun;64(2):116-9 [10814991.001]
  • [Cites] J Immunol. 1995 Apr 15;154(8):3806-13 [7706720.001]
  • [Cites] J Rheumatol. 2001 Jan;28(1):22-8 [11196534.001]
  • [Cites] Arthritis Rheum. 2001 Mar;44(3):550-60 [11263769.001]
  • [Cites] J Exp Med. 1997 Dec 15;186(12):2045-50 [9396774.001]
  • [Cites] Science. 1994 Mar 25;263(5154):1759-62 [7510905.001]
  • [Cites] Anticancer Res. 1997 Sep-Oct;17(5A):3253-8 [9413156.001]
  • [Cites] Arthritis Rheum. 1997 Jun;40(6):1126-9 [9182923.001]
  • [Cites] Clin Exp Med. 2002 May;2(1):13-27 [12049185.001]
  • [Cites] J Pathol. 2001 Jan;193(1):110-6 [11169523.001]
  • [Cites] Am J Med. 2000 Jan;108(1):73-82 [11059443.001]
  • (PMID = 16972019.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / FAS protein, human; 0 / FASLG protein, human; 0 / Fas Ligand Protein; EC 3.4.24.17 / Matrix Metalloproteinase 3
  •  go-up   go-down


11. Rees J, Watt H, Jäger HR, Benton C, Tozer D, Tofts P, Waldman A: Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation. Eur J Radiol; 2009 Oct;72(1):54-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation.
  • Adult low-grade gliomas (LGG) grow slowly, but most eventually undergo malignant transformation.
  • Twenty-seven patients with biopsy-proven, untreated LGG had at least three MRI studies at 6 monthly intervals.
  • [MeSH-minor] Adult. Aged. Cell Transformation, Neoplastic / pathology. Female. Humans. Image Enhancement / methods. Male. Middle Aged. Reproducibility of Results. Risk Assessment. Risk Factors. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18632238.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


12. Jenkinson MD, Smith TS, Haylock B, Husband D, Shenoy A, Vinjamuri S, Walker C, Pietronigro D, Warnke PC: Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma. J Neurooncol; 2010 Aug;99(1):103-13
Hazardous Substances Data Bank. THALLIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063175.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0Z5B2CJX4D / Fluorodeoxyglucose F18; AD84R52XLF / Thallium; U68WG3173Y / Carmustine
  •  go-up   go-down


13. Vieira TC, da Silva MR, Abucham J: The natural history of the R120C PROP1 mutation reveals a wide phenotypic variability in two untreated adult brothers with combined pituitary hormone deficiency. Endocrine; 2006 Dec;30(3):365-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The natural history of the R120C PROP1 mutation reveals a wide phenotypic variability in two untreated adult brothers with combined pituitary hormone deficiency.
  • METHODS: Clinical follow-up and molecular analysis of PROP1 in two adult brothers with CPHD, born from consanguineous parents, and not treated until late adulthood.
  • [MeSH-minor] Adult. Brazil. DNA Mutational Analysis. Humans. Male. Mutation, Missense. Phenotype

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17526949.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Pituitary Hormones; 0 / Prophet of Pit-1 protein
  •  go-up   go-down


14. Nielsen OS, Reichardt P, Christensen TB, Pink D, Daugaard S, Hermans C, Marreaud S, van Glabbeke M, Blay J, Judson I: Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Eur J Cancer; 2006 Sep;42(14):2303-9
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Male. Middle Aged. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16891112.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


15. Falini ML, Elli L, Caramanico R, Bardella MT, Terrani C, Roncoroni L, Doneda L, Forlani F: Immunoreactivity of antibodies against transglutaminase-deamidated gliadins in adult celiac disease. Dig Dis Sci; 2008 Oct;53(10):2697-701
Hazardous Substances Data Bank. CYSTEAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoreactivity of antibodies against transglutaminase-deamidated gliadins in adult celiac disease.
  • AIM: To determine the immunoreactivity of anti-gliadin antibodies from untreated celiac patients to transglutaminase deamidated gliadins.
  • Immunoreactivity of anti-gliadin antibodies from untreated adult celiac patients sera was evaluated by means of a competitive enzyme-linked immunosorbent assay (ELISA) method.
  • CONCLUSIONS: Increased immunoreactivity of transglutaminase deamidated gliadins tested with anti-gliadin antibodies from untreated adult celiac patients supports the hypothesis of a pivotal role of gliadin deamidation in the pathomechanism of celiac disease.
  • [MeSH-minor] Adult. Cysteamine / metabolism. Deamination / drug effects. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male

  • Genetic Alliance. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306039.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 5UX2SD1KE2 / Cysteamine; 9007-90-3 / Gliadin; EC 2.3.2.13 / Transglutaminases
  •  go-up   go-down


16. Nowakowski J, McKenna D, Nadelman RB, Bittker S, Cooper D, Pavia C, Holmgren D, Visintainer P, Wormser GP: Blood cultures for patients with extracutaneous manifestations of Lyme disease in the United States. Clin Infect Dis; 2009 Dec 1;49(11):1733-5
MedlinePlus Health Information. consumer health - Lyme Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, blood culture results were positive for 5 (19.2%; 95% confidence interval, 6.6%-39.4%) of 26 untreated adult patients with extracutaneous manifestations but only for patients with clinical evidence for a short duration of infection.
  • [MeSH-minor] Adult. Borrelia burgdorferi / physiology. Erythema Chronicum Migrans / microbiology. Erythema Chronicum Migrans / pathology. Female. Humans. Lyme Neuroborreliosis / blood. Lyme Neuroborreliosis / microbiology. Lyme Neuroborreliosis / pathology. Male. Middle Aged. United States

  • Genetic Alliance. consumer health - Lyme Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886794.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Grant] United States / PHS HHS / / CCU 21962
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


17. Hamurcu Z, Dönmez-Altuntas H, Patiroglu T: Basal level micronucleus frequency in stimulated lymphocytes of untreated patients with leukemia. Cancer Genet Cytogenet; 2008 Jan 15;180(2):140-4
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal level micronucleus frequency in stimulated lymphocytes of untreated patients with leukemia.
  • Structural chromosomal aberrations have been described in various types of human leukemia.
  • The present study investigated micronucleus (MN) frequency in mitogen-stimulated peripheral blood lymphocytes from 20 newly diagnosed and untreated leukemia patients: 4 with acute lymphoblastic leukemia (ALL), 10 with acute myeloid leukemia (AML), and 6 with chronic lymphocytic leukemia (CLL).
  • The mean MN frequency for untreated patients was 3.65 +/- 1.47 in ALL, 3.55 +/- 1.24 in AML, 3.03 +/- 1.05 in CLL.
  • No differences in MN frequency were seen between leukemia types ALL, AML, and CLL (P = 0.503).
  • The mean basal MN frequency for all patients, regardless of leukemia type, was 3.41 +/- 1.19, which was significantly higher (P = 0.001) than that of 20 age-matched control subjects, 1.87 +/- 0.75.
  • Although no significant relationship was found between age and MN frequency in patients with leukemia (r = 0.050; P = 0.835), the MN frequency in the lymphocytes of healthy control increased regularly and significantly with age (r = 0.531; P = 0.016).
  • These data indicate that the increased baseline MN frequency in lymphocytes of untreated patients with leukemia may reflect genomic instability or deficiency of DNA repair capacity.
  • [MeSH-major] Leukemia / genetics. Lymphocytes / metabolism. Micronuclei, Chromosome-Defective / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Case-Control Studies. Child. Child, Preschool. Female. Humans. Male. Micronucleus Tests. Middle Aged

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206540.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Wu YJ, Li JY, Zhu MQ, Song JH, Zheng WJ: [Application of a four antibody (cMPO/cCD79aalpha/cCD3/CD45) combination to the diagnosis of acute leukemia expressing cross-lineage antigens]. Zhonghua Xue Ye Xue Za Zhi; 2006 Jul;27(7):449-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of a four antibody (cMPO/cCD79aalpha/cCD3/CD45) combination to the diagnosis of acute leukemia expressing cross-lineage antigens].
  • OBJECTIVE: To explore the diagnostic value of intracellular antibody combination in acute leukemia (AL) expressing cross-lineage cell-surface antigens.
  • METHODS: Flow cytometric immunophenotyping using intracellular antibody combination (cMPO/cCD79alpha/cCD3/CD45) was performed additionally in 60 patients who expressed cross-lineage antigens from 269 previously untreated adult AL.
  • RESULTS: Fifty-four of 269 previously untreated adult AL patients who expressed only one kind of intracellular antigen were diagnosed as cross-lineage AL, the percentage of cross-lineage AL in T cell acute lymphoblastic leukemia (T-ALL), B-ALL and acute myeloid leukemia (AML) was 28.6%, 43.6% and 13.4%, respectively.
  • [MeSH-major] Antibodies, Monoclonal. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD3 / immunology. Antigens, CD45 / immunology. Antigens, CD79 / immunology. Antigens, Surface / immunology. Cross Reactions. Female. Flow Cytometry. Humans. Immunophenotyping. Male. Middle Aged. Sensitivity and Specificity

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17147246.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD3; 0 / Antigens, CD79; 0 / Antigens, Surface; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


19. Goodman DW: The consequences of attention-deficit/hyperactivity disorder in adults. J Psychiatr Pract; 2007 Sep;13(5):318-27
Hazardous Substances Data Bank. ATOMOXETINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although treatments are available for adult ADHD, many patients never receive an accurate diagnosis that would afford them appropriate therapeutic intervention.
  • If left untreated, adult ADHD can cause significant personal, social, and economic burdens that can have a negative impact on overall quality of life.
  • [MeSH-minor] Achievement. Adult. Age Factors. Amphetamine / therapeutic use. Atomoxetine Hydrochloride. Cognitive Therapy. Combined Modality Therapy. Comorbidity. Disease Progression. Female. Health Care Costs. Humans. Impulsive Behavior / diagnosis. Impulsive Behavior / psychology. Male. Mental Disorders / diagnosis. Mental Disorders / drug therapy. Mental Disorders / epidemiology. Methylphenidate / therapeutic use. Propylamines / therapeutic use. Quality of Life. Sex Distribution. Social Adjustment. Substance-Related Disorders / diagnosis. Substance-Related Disorders / epidemiology. Substance-Related Disorders / psychology

  • Genetic Alliance. consumer health - Attention Deficit Disorder.
  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLPHENIDATE .
  • Hazardous Substances Data Bank. AMPHETAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17890980.001).
  • [ISSN] 1527-4160
  • [Journal-full-title] Journal of psychiatric practice
  • [ISO-abbreviation] J Psychiatr Pract
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Propylamines; 207ZZ9QZ49 / Methylphenidate; 57WVB6I2W0 / Atomoxetine Hydrochloride; CK833KGX7E / Amphetamine
  • [Number-of-references] 74
  •  go-up   go-down


20. Jiang XJ, Wang JS, Fang Q: [Gene expression of breast cancer resistance protein in adult acute lymphocytic leukemia and its clinical significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb;16(1):31-4
Genetic Alliance. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gene expression of breast cancer resistance protein in adult acute lymphocytic leukemia and its clinical significance].
  • The objective of this study was to investigate the relationship between the expressions of breast cancer resistance protein (BCRP) gene and drug resistance as well as prognosis in adult patients with acute lymphocytic leukemia (ALL).
  • Semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR) was used to detect the expression of BCRP gene in 97 adult patients with acute lymphocytic leukemia (ALL) and 30 normal subjects.
  • The results showed that the positive ratio of BCRP gene expression in untreated group was 28.7%, in contrast that in refractory and relapsed patients was 51.2%.
  • It is concluded that the high expression of BCRP gene may induce clinical drug resistance, and may be an unfavorable factor for prognosis in adult patients with acute lymphocytic leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18315895.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Neoplasm Proteins
  •  go-up   go-down


21. Robak T: Alemtuzumab in the treatment of chronic lymphocytic leukemia. BioDrugs; 2005;19(1):9-22
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab in the treatment of chronic lymphocytic leukemia.
  • In 2001, alemtuzumab was approved in the US and Europe to treat B-cell chronic lymphocytic leukemia (CLL) that had been treated previously with alkylating agents and was refractory to fludarabine.
  • In heavily pretreated patients this MAb is able to produce response rates of about 40%, and in symptomatic, previously untreated patients response rates of more than 80% can be achieved.
  • Moreover its in vivo use before or after SCT may also potentially result in depletion of residual leukemia cells, especially in the autologous setting.
  • Adverse events associated with alemtuzumab include acute first-dose reaction, hematologic toxicity, and infectious complications.
  • [MeSH-major] Antigens, CD / immunology. Antigens, Neoplasm / immunology. Glycoproteins / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / pharmacokinetics. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / adverse effects. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Drug Administration Schedule. Half-Life. Humans. Infusions, Intravenous. Middle Aged. Rituximab. Stem Cell Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691213.001).
  • [ISSN] 1173-8804
  • [Journal-full-title] BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • [ISO-abbreviation] BioDrugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 99
  •  go-up   go-down


22. Carli L, Montecucco C, Rossetto O: Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve; 2009 Sep;40(3):374-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • N-CAM is a membrane glycoprotein that accumulates on muscle fibers after denervation and is not expressed in untreated adult muscle.

  • MedlinePlus Health Information. consumer health - Botox.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19618426.001).
  • [ISSN] 0148-639X
  • [Journal-full-title] Muscle & nerve
  • [ISO-abbreviation] Muscle Nerve
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP06133
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neural Cell Adhesion Molecules; 0 / Neuromuscular Agents; EC 3.4.24.69 / Botulinum Toxins, Type A
  •  go-up   go-down


23. Taricco LD, Aoki SS: Rehabilitation of an adult patient with arthrogryposis multiplex congenita treated with an external fixator. Am J Phys Med Rehabil; 2009 May;88(5):431-4
Genetic Alliance. consumer health - Arthrogryposis Multiplex Congenita.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rehabilitation of an adult patient with arthrogryposis multiplex congenita treated with an external fixator.
  • Reports that describe the experience of a rehabilitation program for adult patients with arthrogryposis are rare.
  • We describe the treatment of an adult patient who had not received previous surgery or rehabilitation.
  • This report aims to emphasize the good result of interdisciplinary care of a previously untreated adult patient with arthrogryposis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620956.001).
  • [ISSN] 1537-7385
  • [Journal-full-title] American journal of physical medicine & rehabilitation
  • [ISO-abbreviation] Am J Phys Med Rehabil
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Churchwell MI, Beland FA, Doerge DR: Quantification of O6-methyl and O6-ethyl deoxyguanosine adducts in C57BL/6N/Tk+/- mice using LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Nov 21;844(1):60-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This sensitivity permitted evaluation of adduct levels in livers from separate groups of untreated adult C57BL/6N/Tk(+/-) and C57BL/6N X Sv129 mice (undetectable to 5.5+/-6.7 O(6)Me-dG/10(8) nucleotides; undetectable to 0.04 O(6)Et-dG/10(8) nucleotides).
  • Treatment of adult C57BL/6N/Tk(+/-) mice with equimolar doses (342micromol/kg body weight) of N-methyl-N-nitrosourea and N-ethyl-N-nitrosourea produced adduct levels in liver of 1700+/-80 O(6)Me-dG/10(8) nucleotides and 260+/-60 O(6)Et-dG/10(8) nucleotides, respectively, when assessed 4h after dosing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16931193.001).
  • [ISSN] 1570-0232
  • [Journal-full-title] Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
  • [ISO-abbreviation] J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 50704-46-6 / O(6)-ethyl-2'-deoxyguanosine; 964-21-6 / O(6)-methyl-2'-deoxyguanosine; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


25. Ueyama C, Akashiba H, Nakayama K, Nakayama KI, Nishiyama N, Matsuki N: Ablation of p27 enhance kainate-induced seizure and hippocampal degeneration. Neuroreport; 2007 Nov 19;18(17):1781-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No change was observed in hippocampal cell viability in untreated adult p27 heterozygous and homozygous mice compared with wild type (+/+).

  • MedlinePlus Health Information. consumer health - Seizures.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18090311.001).
  • [ISSN] 0959-4965
  • [Journal-full-title] Neuroreport
  • [ISO-abbreviation] Neuroreport
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Excitatory Amino Acid Agonists; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 9007-49-2 / DNA; SIV03811UC / Kainic Acid
  •  go-up   go-down


26. Olsvik PA, Lie KK, Jordal AE, Nilsen TO, Hordvik I: Evaluation of potential reference genes in real-time RT-PCR studies of Atlantic salmon. BMC Mol Biol; 2005;6:21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The relative transcription levels of genes encoding 18S rRNA, S20 ribosomal protein, beta-actin, glyceraldehyde-3P-dehydrogenase (GAPDH), and two paralog genes encoding elongation factor 1A (EF1AA and EF1AB) were quantified in gills, liver, head kidney, spleen, thymus, brain, muscle, and posterior intestine in six untreated adult fish, in addition to a group of individuals that went through smoltification.
  • Based on calculations performed with the geNorm VBA applet, which determines the most stable genes from a set of tested genes in a given cDNA sample, the ranking of the examined genes in adult Atlantic salmon was EF1AB>EF1AA>beta-actin>18S rRNA>S20>GAPDH.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 2001 Dec 1;299(1):63-70 [11726185.001]
  • [Cites] Biotechniques. 2000 Aug;29(2):332-7 [10948434.001]
  • [Cites] Comp Biochem Physiol B Biochem Mol Biol. 2002 Dec;133(4):609-46 [12470823.001]
  • [Cites] J Mol Med (Berl). 2003 Sep;81(9):536-48 [12898041.001]
  • [Cites] Vet Parasitol. 2003 Dec 1;118(1-2):169-74 [14651887.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 23;313(4):856-62 [14706621.001]
  • [Cites] Biotechnol Lett. 2004 Mar;26(6):509-15 [15127793.001]
  • [Cites] Biotechniques. 2004 Jul;37(1):112-4, 116, 118-9 [15283208.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Biochim Biophys Acta. 1997 Jan 3;1350(1):1-5 [9003448.001]
  • [Cites] Immunol Rev. 1998 Dec;166:153-7 [9914910.001]
  • [Cites] Biochim Biophys Acta. 1999 Jul 13;1432(2):159-84 [10407139.001]
  • [Cites] Anal Biochem. 2004 Dec 1;335(1):30-41 [15519568.001]
  • [Cites] Kidney Int. 2004 Dec;66(6):2308-14 [15569320.001]
  • [Cites] Crit Rev Biochem Mol Biol. 2004 Jul-Aug;39(4):197-216 [15596551.001]
  • [Cites] Mol Cell Probes. 2005 Apr;19(2):101-9 [15680211.001]
  • [Cites] BMC Mol Biol. 2005;6:4 [15720708.001]
  • [Cites] Mol Immunol. 2005 Jun;42(10):1225-34 [15829311.001]
  • [Cites] Genes Immun. 2005 Jun;6(4):279-84 [15815687.001]
  • [Cites] J Mol Endocrinol. 2005 Jun;34(3):597-601 [15956331.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2005 Jul;141(3):314-23 [16107325.001]
  • [Cites] Virol J. 2005;2:7 [15705200.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • (PMID = 16293192.001).
  • [ISSN] 1471-2199
  • [Journal-full-title] BMC molecular biology
  • [ISO-abbreviation] BMC Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Peptide Elongation Factor 1; 0 / RNA, Ribosomal, 18S; 0 / Ribosomal Proteins; 0 / ribosomal protein S20; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  • [Other-IDs] NLM/ PMC1314898
  •  go-up   go-down


27. Luzzati F, De Marchis S, Fasolo A, Peretto P: Neurogenesis in the caudate nucleus of the adult rabbit. J Neurosci; 2006 Jan 11;26(2):609-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurogenesis in the caudate nucleus of the adult rabbit.
  • Stem cells with the potential to give rise to new neurons reside in different regions of the adult rodents CNS, but in vivo only the hippocampal dentate gyrus and the subventricular zone-olfactory bulb system are neurogenic under physiological condition.
  • Accordingly, we have demonstrated recently that, in the adult rabbit brain, striking structural plasticity persists in several cortical and subcortical areas.
  • Here, by using markers for immature and mature neuronal and glial cell types, endogenous and exogenously administered cell-proliferation markers, intraventricular cell tracer injections coupled to confocal analysis, three-dimensional reconstructions, and in vitro tissue cultures, we demonstrate the existence of newly formed neurons in the caudate nucleus of normal, untreated, adult rabbit.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16407559.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Calbindin 2; 0 / Fluoresceins; 0 / Fluorescent Dyes; 0 / Nerve Tissue Proteins; 0 / S100 Calcium Binding Protein G; 136832-63-8 / 5-chloromethylfluorescein
  •  go-up   go-down


28. Laron Z, Ginsberg S, Webb M: Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion - preliminary report. Growth Horm IGF Res; 2008 Oct;18(5):434-8
Genetic Alliance. consumer health - Laron syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUBJECTS: We studied 11 untreated adult patients with LS (5M, 6F), five girls with LS treated by IGF-I and five adult patients with GH gene deletion (3M, 3F), four previously treated by hGH in childhood.
  • RESULTS: Six out of 11 adult patients with LS, two out of the five IGF-I treated girls with LS and three out of five adult hGH gene deletion patients were found to have NAFLD (nonalcoholic fatty liver disease).
  • CONCLUSION: NAFLD is a frequent complication in untreated and treated congenital IGF-I deficiency.
  • [MeSH-minor] Adult. Female. Humans. Insulin Resistance. Insulin-Like Growth Factor I / deficiency. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18462969.001).
  • [ISSN] 1096-6374
  • [Journal-full-title] Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • [ISO-abbreviation] Growth Horm. IGF Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


29. Rakusan D, Kujal P, Kramer HJ, Husková Z, Vanourková Z, Vernerová Z, Mrázová I, Thumová M, Cervenka L, Vanecková I: Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. Am J Physiol Renal Physiol; 2010 Oct;299(4):F758-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effects of the human renin inhibitor aliskiren on blood pressure (BP), end-organ damage, proteinuria, and tissue and plasma angiotensin (ANG) II levels in young and adult heterozygous Ren-2 transgenic rats (TGR) were evaluated and compared with the effect of the ANG type 1 (AT(1)) receptor blocker losartan during treatment and after 12 days after the withdrawal of drug treatments.
  • BP was monitored by telemetry from the age of 32 days on (young rats) and at 100 days (adult rats).
  • Aliskiren (10 mg·kg(-1)·day(-1) in osmotic minipumps) or losartan (5 mg·kg(-1)·day(-1) in drinking water) treatment was applied for 28 days in young rats and for 70 days in adult rats.
  • In young untreated TGR, severe hypertension rapidly evolved.
  • Adult untreated TGR exhibited stable established hypertension.
  • Both aliskiren and losartan fully prevented the development of hypertension and cardiac hypertrophy in young TGR and normalized BP and cardiac hypertrophy in adult TGR.
  • After cessation of aliskiren treatment in both young and adult TGR BP and cardiac hypertrophy were persistently reduced, while after losartan withdrawal BP and cardiac hypertrophy rapidly increased.
  • In adult aliskiren-treated rats proteinuria was significantly reduced compared with losartan (the effect persisting after withdrawal of treatment), and this decrease strongly correlated with normalization of glomerular size in these animals.

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • Hazardous Substances Data Bank. Losartan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20668096.001).
  • [ISSN] 1522-1466
  • [Journal-full-title] American journal of physiology. Renal physiology
  • [ISO-abbreviation] Am. J. Physiol. Renal Physiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amides; 0 / Antihypertensive Agents; 0 / Fumarates; 0 / Ren2 protein, rat; 11128-99-7 / Angiotensin II; 502FWN4Q32 / aliskiren; EC 3.4.23.15 / Renin; JMS50MPO89 / Losartan
  •  go-up   go-down


30. Eslambolchi S, Woodside DG, Rossouw PE: A descriptive study of mandibular incisor alignment in untreated subjects. Am J Orthod Dentofacial Orthop; 2008 Mar;133(3):343-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A descriptive study of mandibular incisor alignment in untreated subjects.
  • METHODS: In this study, we describe the longitudinal dental changes in untreated children (n = 15) who had records at 3 times and in an untreated adult group (n = 18) (parents) who had records for 2 times.
  • CONCLUSIONS: These results underline the importance of studies showing that untreated dentitions change over time.
  • [MeSH-minor] Adolescent. Adult. Cephalometry. Child. Female. Humans. Longitudinal Studies. Male. Maxillofacial Development / physiology. Odontometry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331931.001).
  • [ISSN] 1097-6752
  • [Journal-full-title] American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics
  • [ISO-abbreviation] Am J Orthod Dentofacial Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Knuchel MC, Tomasik Z, Speck RF, Lüthy R, Schüpbach J: Ultrasensitive quantitative HIV-1 p24 antigen assay adapted to dried plasma spots to improve treatment monitoring in low-resource settings. J Clin Virol; 2006 May;36(1):64-7
HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: DPS from 47 HIV-seropositive, treated or untreated adult individuals and 30 healthy individuals were examined.
  • [MeSH-minor] Adult. Anti-HIV Agents / therapeutic use. Case-Control Studies. Child. Costs and Cost Analysis. Enzyme-Linked Immunosorbent Assay. Evaluation Studies as Topic. HIV Antibodies / blood. HIV Antibodies / chemistry. HIV Antigens / blood. HIV Seropositivity. Hot Temperature. Humans. Protein Denaturation. Sensitivity and Specificity. Treatment Outcome. Viral Load

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16431154.001).
  • [ISSN] 1386-6532
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / HIV Antibodies; 0 / HIV Antigens; 0 / HIV Core Protein p24
  •  go-up   go-down


32. Li LP, Shiao AS, Chen LF, Niddam DM, Chang SY, Lien CF, Lee SK, Hsieh JC: Healthy-side dominance of middle- and long-latency neuromagnetic fields in idiopathic sudden sensorineural hearing loss. Eur J Neurosci; 2006 Aug;24(3):937-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study used magnetoencephalography to investigate auditory-evoked magnetic fields [a component of the middle-latency auditory evoked fields peaking at approximately 50 ms (P50m) and a component of the long-latency auditory evoked fields peaking at approximately 100 ms (N100m)] on stimulation of both healthy and affected ears in patients with acute unilateral idiopathic sudden sensorineural hearing loss (ISSNHL) of moderate degree in order to elucidate the functional plasticity of the auditory system.
  • Sixteen right-handed, previously untreated adult patients with acute unilateral left (n = 8) or right (n = 8) ISSNHL of moderate degree were studied.
  • [MeSH-minor] Acoustic Stimulation. Adult. Evoked Potentials, Auditory / physiology. Female. Humans. Magnetoencephalography. Male. Middle Aged. Reaction Time / physiology

  • Genetic Alliance. consumer health - Sensorineural hearing loss.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16930421.001).
  • [ISSN] 0953-816X
  • [Journal-full-title] The European journal of neuroscience
  • [ISO-abbreviation] Eur. J. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


33. Winquist E, Knox J, Ayoub JP, Wood L, Wainman N, Reid GK, Pearce L, Shah A, Eisenhauer E: Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs; 2006 Mar;24(2):159-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Untreated adult patients with measurable MRC were treated with MG98 at a dose of 360 mg/m2 via 2-h iv infusion twice weekly for three consecutive weeks out of four.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Canada. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. RNA, Messenger / blood

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16502349.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DMAP1 protein, human; 0 / MG 98 phosphorothioate antisense oligodeoxynucleotide; 0 / Oligodeoxyribonucleotides; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Thionucleotides
  •  go-up   go-down


34. Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, Vianelli N, Defina M, Tieghi A, Amadori S, Campagna S, Ferrara F, Angelucci E, Usala E, Cantoni S, Visani G, Fornaro A, Rizzi R, De Stefano V, Casulli F, Battista ML, Isola M, Soldano F, Gamba E, Fanin R: Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood; 2010 Apr 8;115(14):2755-62
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This randomized trial investigated rituximab efficacy in previously untreated adult ITP patients with a platelet count of 20 x 10(9)/L or less.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Middle Aged. Platelet Count. Rituximab. Time Factors


35. Goetz AK, Rockett JC, Ren H, Thillainadarajah I, Dix DJ: Inhibition of rat and human steroidogenesis by triazole antifungals. Syst Biol Reprod Med; 2009 Dec;55(5-6):214-26
Hazardous Substances Data Bank. PROPICONAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hormone production was measured in testis organ cultures from untreated adult and neonatal rats, following in vitro exposure to 1, 10, or 100 muM of myclobutanil or triadimefon.
  • Myclobutanil and triadimefon reduced media levels of testosterone by 40-68% in the adult and neonatal testis culture, and altered steroid production in a manner that indicated CYP17-hydroxylase/17,20 lyase (CYP17A1) inhibition at the highest concentration tested.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TRIADIMEFON .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19938956.001).
  • [ISSN] 1939-6376
  • [Journal-full-title] Systems biology in reproductive medicine
  • [ISO-abbreviation] Syst Biol Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Nitriles; 0 / Steroids; 0 / Triazoles; 0 / systhane; 142KW8TBSR / propiconazole; 3XMK78S47O / Testosterone; 43121-43-3 / triadimefon; EC 1.14.99.9 / CYP17A1 protein, human; EC 1.14.99.9 / Steroid 17-alpha-Hydroxylase
  •  go-up   go-down


36. Ling Y, Cao X, Yu Z, Ruan C: Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol; 2007 Oct;79(4):310-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome.
  • In this study, we investigated the amounts of circulating myeloid DCs (mDCs), plasmacytoid DCs (pDCs), and CD4(+)Foxp3(+) Treg cells in 26 untreated adult patients with chronic ITP.
  • [MeSH-minor] Adult. Antigens, CD11c / immunology. CD4 Lymphocyte Count. Chronic Disease. Down-Regulation / drug effects. Female. Humans. Immunosuppression. Male. Middle Aged. Myeloid Cells / immunology. Myeloid Cells / pathology. Plasma Cells / immunology. Plasma Cells / pathology. Platelet Count

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692100.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD11c; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Glucocorticoids; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


37. Morita Y, Kanamaru A, Miyazaki Y, Imanishi D, Yagasaki F, Tanimoto M, Kuriyama K, Kobayashi T, Imoto S, Ohnishi K, Naoe T, Ohno R: Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. Int J Hematol; 2010 Jan;91(1):97-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group.
  • A total of 120 patients with high-risk myelodysplastic syndrome (MDS) and AML progressed from MDS (MDS-AML) were registered in a randomized controlled study of the Japan Adult Leukemia Study Group (JALSG).
  • Untreated adult patients with high-risk MDS and MDS-AML were randomly assigned to receive either idarubicin and cytosine arabinoside (IDR/Ara-C) (Group A) or low-dose cytosine arabinoside and aclarubicin (CA) (Group B).
  • [MeSH-major] Aclarubicin / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cytarabine / administration & dosage. Idarubicin / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Female. Humans. Japan. Male. Middle Aged. Remission Induction. Risk Factors. Survival Analysis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20047095.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 74KXF8I502 / Aclarubicin; ZRP63D75JW / Idarubicin
  •  go-up   go-down


38. McKenzie EJ, Taylor PR, Stillion RJ, Lucas AD, Harris J, Gordon S, Martinez-Pomares L: Mannose receptor expression and function define a new population of murine dendritic cells. J Immunol; 2007 Apr 15;178(8):4975-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have now observed that while MR(+) cells are consistently absent from T cell areas of spleen and mesenteric lymph nodes (LN), peripheral LN of untreated adult mice contain a minor population of MR(+)MHCII(+) in the paracortex.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17404279.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin G; 0 / Lectins, C-Type; 0 / Lipopolysaccharides; 0 / Mannose-Binding Lectins; 0 / Receptors, Cell Surface; 0 / mannose receptor
  •  go-up   go-down


39. Lifschitz A, Virkel G, Ballent M, Sallovitz J, Pis A, Lanusse C: Moxidectin and ivermectin metabolic stability in sheep ruminal and abomasal contents. J Vet Pharmacol Ther; 2005 Oct;28(5):411-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both compounds were incubated under anaerobic conditions during 2, 6 and 24 h in ruminal and abomasal contents collected from untreated adult sheep.
  • Neither MXD nor IVM suffered metabolic conversion and/or chemical degradation after 24-h incubation in ruminal and abomasal contents collected from adult sheep.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16207302.001).
  • [ISSN] 0140-7783
  • [Journal-full-title] Journal of veterinary pharmacology and therapeutics
  • [ISO-abbreviation] J. Vet. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthelmintics; 0 / Macrolides; 51570-36-6 / milbemycin; 70288-86-7 / Ivermectin
  •  go-up   go-down


40. Dillo W, Göke A, Prox-Vagedes V, Szycik GR, Roy M, Donnerstag F, Emrich HM, Ohlmeier MD: Neuronal correlates of ADHD in adults with evidence for compensation strategies--a functional MRI study with a Go/No-Go paradigm. Ger Med Sci; 2010;8:Doc09
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: fMRI was used to compare brain activation in 15 untreated adult patients with ADHD and 15 healthy reference volunteers during performance of a Go/No-Go task.
  • CONCLUSION: We hypothesize that the enhanced activity is due to the ability of adult ADHD patients to compensate their deficits for a short time, which is demonstrated in our study by equal task performance in both groups.
  • [MeSH-minor] Adaptation, Physiological / physiology. Adult. Female. Frontal Lobe / physiopathology. Gyrus Cinguli / physiopathology. Humans. Male. Parietal Lobe / physiopathology. Psychomotor Performance. Young Adult

  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Psychol Rev. 2006 Aug;26(4):445-65 [16500007.001]
  • [Cites] Biol Psychiatry. 2003 May 15;53(10):871-8 [12742674.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10330-4 [17563353.001]
  • [Cites] Neuroimage. 2008 Aug 1;42(1):36-41 [18511306.001]
  • [Cites] Biol Psychol. 2003 Oct;64(1-2):119-41 [14602358.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2004 Nov;43(11):1430-40 [15502603.001]
  • [Cites] N Engl J Med. 1990 Nov 15;323(20):1361-6 [2233902.001]
  • [Cites] Neuropsychologia. 1997 Sep;35(9):1261-73 [9364496.001]
  • [Cites] J Clin Psychiatry. 1998;59 Suppl 7:59-68 [9680054.001]
  • [Cites] Hum Brain Mapp. 1998;6(4):270-82 [9704265.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14494-9 [9826728.001]
  • [Cites] Am J Psychiatry. 1999 Jun;156(6):891-6 [10360128.001]
  • [Cites] Biol Psychiatry. 1999 Jun 15;45(12):1542-52 [10376114.001]
  • [Cites] Neuroimage. 1999 Oct;10(4):385-96 [10493897.001]
  • [Cites] Biol Psychiatry. 2005 Mar 1;57(5):439-47 [15737657.001]
  • [Cites] Neuropsychology. 2005 May;19(3):390-402 [15910125.001]
  • [Cites] Am J Psychiatry. 2005 Jun;162(6):1067-75 [15930054.001]
  • [Cites] Neuroimage. 2005 Nov 1;28(2):429-39 [16122945.001]
  • [Cites] Nature. 2006 Mar 30;440(7084):676-9 [16572172.001]
  • [Cites] Am J Psychiatry. 2006 Jun;163(6):1033-43 [16741204.001]
  • [Cites] J Cogn Neurosci. 2006 May;18(5):766-80 [16768376.001]
  • [Cites] Am J Psychiatry. 2000 Feb;157(2):278-80 [10671402.001]
  • [Cites] Pediatrics. 2000 May;105(5):1158-70 [10836893.001]
  • [Cites] Hum Brain Mapp. 2001 Feb;12(2):100-9 [11169874.001]
  • [Cites] Hum Brain Mapp. 2001 Mar;12(3):131-43 [11170305.001]
  • [Cites] Clin Neuropharmacol. 2001 Jan-Feb;24(1):2-10 [11290875.001]
  • [Cites] Nervenarzt. 2002 Sep;73(9):830-8 [12215873.001]
  • [Cites] Hum Brain Mapp. 2006 Dec;27(12):973-93 [16683265.001]
  • (PMID = 20421953.001).
  • [ISSN] 1612-3174
  • [Journal-full-title] German medical science : GMS e-journal
  • [ISO-abbreviation] Ger Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2858877
  • [Keywords] NOTNLM ; ADHD / Go/No-Go task / fMRI / neuronal compensation
  •  go-up   go-down


41. Tektas OY, Hammer CM, Danias J, Candia O, Gerometta R, Podos SM, Lütjen-Drecoll E: Morphologic changes in the outflow pathways of bovine eyes treated with corticosteroids. Invest Ophthalmol Vis Sci; 2010 Aug;51(8):4060-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The TM of four adult Braford cow eyes treated with 0.5% prednisolone eye drops three times daily for 7 weeks and their contralateral eyes treated with artificial tear preparation and that of two adult untreated Braford cows and untreated young calves eyes were analyzed with light and electron microscopy.
  • In the untreated Braford controls and in untreated calf eyes, plaques were nearly absent.
  • These changes were not seen in contralateral eyes or eyes of untreated animals.

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2229-38 [10892867.001]
  • [Cites] Am J Ophthalmol. 1967 Feb;63(2):283-9 [5335424.001]
  • [Cites] Exp Eye Res. 2003 Dec;77(6):757-65 [14609564.001]
  • [Cites] Arch Ophthalmol. 2004 Oct;122(10):1492-7 [15477461.001]
  • [Cites] Am J Ophthalmol. 1970 Apr;69(4):608-10 [5437825.001]
  • [Cites] Trans Am Ophthalmol Soc. 1969;67:339-54 [5381311.001]
  • [Cites] Exp Eye Res. 1973 Oct 10;17(1):19-31 [4356557.001]
  • [Cites] Trans Am Ophthalmol Soc. 1977;75:353-81 [613525.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1979 Sep;18(9):918-29 [113361.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1981 Oct;21(4):563-73 [7287346.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1981 Oct;21(4):574-85 [7287347.001]
  • [Cites] Trans Ophthalmol Soc U K. 1986;105 ( Pt 2):180-95 [3467494.001]
  • [Cites] Curr Eye Res. 1988 Aug;7(8):799-807 [3180831.001]
  • [Cites] Exp Eye Res. 1991 Jun;52(6):681-90 [1855543.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1992 Jun;33(7):2242-50 [1607235.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1993 Nov;34(12):3386-95 [8225873.001]
  • [Cites] Exp Eye Res. 1993 Oct;57(4):461-8 [8282032.001]
  • [Cites] Korean J Ophthalmol. 1996 Jun;10(1):29-33 [8755199.001]
  • [Cites] Arch Ophthalmol. 1997 Mar;115(3):375-83 [9076211.001]
  • [Cites] Ophthalmologica. 1997;211(3):140-6 [9176894.001]
  • [Cites] Exp Eye Res. 1998 Jun;66(6):731-8 [9657905.001]
  • [Cites] Int J Mol Med. 1998 Feb;1(2):339-46 [9852235.001]
  • [Cites] Singapore Med J. 1999 May;40(5):345-8 [10489493.001]
  • [Cites] Arch Ophthalmol. 1962 Dec;68:742-53 [13967694.001]
  • [Cites] Arch Ophthalmol. 1963 Oct;70:482-91 [14078870.001]
  • [Cites] Arch Ophthalmol. 1963 Oct;70:492-9 [14078871.001]
  • [Cites] Arch Ophthalmol. 1963 Oct;70:500-7 [14078872.001]
  • [Cites] Invest Ophthalmol. 1965 Apr;4:198-205 [14283013.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Sep;47(9):4042-9 [16936121.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):1021-8 [18386038.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1255-63 [18952927.001]
  • [Cites] Exp Eye Res. 2009 Apr;88(4):752-9 [18977348.001]
  • [Cites] Exp Eye Res. 2009 Apr;88(4):769-75 [19114037.001]
  • [Cites] Exp Eye Res. 2009 Nov;89(5):648-59 [19540832.001]
  • [Cites] Exp Eye Res. 2004 Nov;79(5):649-63 [15500824.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4419-26 [14507888.001]
  • (PMID = 20237246.001).
  • [ISSN] 1552-5783
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / EY13749; United States / NEI NIH HHS / EY / R01 EY013749; United States / NEI NIH HHS / EY / R03 EY016050; United States / NEI NIH HHS / EY / R01 EY000160; United States / NEI NIH HHS / EY / EY00160; United States / NEI NIH HHS / EY / EY016050
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Collagen Type VI; 0 / Glucocorticoids; 9PHQ9Y1OLM / Prednisolone
  • [Other-IDs] NLM/ PMC2910640
  •  go-up   go-down


42. Silbergeld A, Lilos P, Laron Z: Foot length before and during insulin-like growth factor-I treatment of children with laron syndrome compared to human growth hormone treatment of children with isolated growth hormone deficiency. J Pediatr Endocrinol Metab; 2007 Dec;20(12):1325-8
MedlinePlus Health Information. consumer health - Foot Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifteen non-treated adult patients with LS were also included in the study.
  • METHODS: Measurements of foot length were recorded without treatment and monitored during 9 years of treatment in the children and in the untreated adult patients.
  • Adult foot size of untreated patients with LS is small but less retarded than the height deficit.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Body Height / drug effects. Child. Female. Hormone Replacement Therapy / methods. Humans. Male. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Growth Hormone Deficiency.
  • Genetic Alliance. consumer health - Laron syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341092.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  •  go-up   go-down


43. Holsberger DR, Kiesewetter SE, Cooke PS: Regulation of neonatal Sertoli cell development by thyroid hormone receptor alpha1. Biol Reprod; 2005 Sep;73(3):396-403
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neonatal hypothyroidism increases adult Sertoli cell populations by extending Sertoli cell proliferation.
  • Triiodothyronine (T3) treatment from birth until Postnatal Day 10 reduced Sertoli cell proliferation to minimal levels in WT and TRbetaKO mice versus that in their untreated controls, whereas T3 had a diminished effect on TRalphaKO Sertoli cell proliferation.
  • In untreated adult TRalphaKO mice, Sertoli cell number, testis weight, and daily sperm production were increased or trended toward an increase, but the increase in magnitude was smaller than that seen in WT mice following neonatal hypothyroidism.
  • Conversely, in TRbetaKO mice, Sertoli cell number, testis weight, and daily sperm production were similar to those in untreated WT mice.
  • In addition, Sertoli cell number and testis weight in adult WT and TRbetaKO mice showed comparable increases following hypothyroidism.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858214.001).
  • [ISSN] 0006-3363
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / C06 RR16515; United States / NIEHS NIH HHS / ES / ES11590; United States / NICHD NIH HHS / HD / T32 HD07028
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn1b protein, mouse; 0 / Cell Cycle Proteins; 0 / Thyroid Hormone Receptors alpha; 0 / Tumor Suppressor Proteins; 06LU7C9H1V / Triiodothyronine; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


44. Ginsberg S, Laron Z, Bed MA, Vaisman N: The obesity of patients with Laron Syndrome is not associated with excessive nutritional intake. Obes Res Clin Pract; 2009 Mar;3(1):1-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY: To study the metabolic parameters which may affect the excessive weight of treated and untreated patients with Laron Syndrome.
  • SUBJECTS: Nine untreated adult subjects with Laron Syndrome (6 female subjects, 3 male subjects) aged 28-53 years and 4 girls with Laron Syndrome treated by insulin-like growth factor-I (IGF-I) 120-150 μg/kg/d were included in the study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 Asian Oceanian Association for the Study of Obesity . Published by Elsevier Ltd. All rights reserved.
  • (PMID = 24345535.001).
  • [ISSN] 1871-403X
  • [Journal-full-title] Obesity research & clinical practice
  • [ISO-abbreviation] Obes Res Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


45. Gutiérrez LP, Kołtowska-Häggström M, Jönsson PJ, Mattsson AF, Svensson D, Westberg B, Luger A: Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiol Drug Saf; 2008 Jan;17(1):90-102
Hazardous Substances Data Bank. CHOLESTEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study was based on 11,374 treated (40,000 patient-years of observation) and 263 untreated adult GH deficient patients from 30 countries, in whom background characteristics, clinical values such as lipids and body composition, quality of life (QoL) and GH dosage as well as safety profile were evaluated.
  • RESULTS: The study depicts the clinical picture of adult patients with GH deficiency managed in current clinical settings.
  • [MeSH-minor] Adult. Body Composition / drug effects. Cholesterol / blood. Evidence-Based Medicine. Female. Humans. Male. Prospective Studies. Quality of Life. Recombinant Proteins. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17957812.001).
  • [ISSN] 1053-8569
  • [Journal-full-title] Pharmacoepidemiology and drug safety
  • [ISO-abbreviation] Pharmacoepidemiol Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 12629-01-5 / Human Growth Hormone; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


46. Allan CM, Garcia A, Spaliviero J, Jimenez M, Handelsman DJ: Maintenance of spermatogenesis by the activated human (Asp567Gly) FSH receptor during testicular regression due to hormonal withdrawal. Biol Reprod; 2006 May;74(5):938-44
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Testes of untreated adult Tg-FSHR* males were equivalent in weight to nontransgenic controls but exhibited increased total Sertoli cell (24%) and spermatogonia (34%) numbers and nonsignificantly elevated spermatocyte-spermatid numbers (13%-17%).
  • After 6 wk of T withdrawal, spermatogonia, spermatocyte, and postmeiotic spermatid numbers in Tg-FSHR* Gnrh1(-/-) testes decreased to levels found in untreated Tg-FSHR* Gnrh1(-/-) testes.
  • Basal serum T levels in untreated Tg-FSHR* Gnrh1(-/-) males were 2-fold higher than Gnrh1(-/-) controls, but following T treatment/withdrawal, serum T and epididymal weights declined to basal levels found in nontransgenic Gnrh1(-/-) mice.

  • Hazardous Substances Data Bank. GLYCINE .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Biol Reprod. 2006 Jun;74(6):1121. Handelsman, David J [added]
  • (PMID = 16452461.001).
  • [ISSN] 0006-3363
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Gonadotropins; 0 / Receptors, FSH; 30KYC7MIAI / Aspartic Acid; 33515-09-2 / Gonadotropin-Releasing Hormone; TE7660XO1C / Glycine
  •  go-up   go-down


47. De Marinis E, Martini C, Trentalance A, Pallottini V: Sex differences in hepatic regulation of cholesterol homeostasis. J Endocrinol; 2008 Sep;198(3):635-43
Hazardous Substances Data Bank. CHOLESTEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our data support that physiological differences in proteins involved in cholesterol balance are present between the sexes and, in particular, 3-hydroxy 3-methylglutaryl coenzyme A reductase shows lower activity and expression in female and 17-beta-estradiol-treated male rats than in adult untreated male.

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18603607.001).
  • [ISSN] 1479-6805
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insig1 protein, rat; 0 / Membrane Proteins; 0 / Sterol Regulatory Element Binding Protein 2; 4TI98Z838E / Estradiol; 97C5T2UQ7J / Cholesterol; EC 1.1.1.- / Hydroxymethylglutaryl CoA Reductases
  •  go-up   go-down


48. Neema M, Navarro-Quiroga I, Chechlacz M, Gilliams-Francis K, Liu J, Lamonica K, Lin SL, Naegele JR: DNA damage and nonhomologous end joining in excitotoxicity: neuroprotective role of DNA-PKcs in kainic acid-induced seizures. Hippocampus; 2005;15(8):1057-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brains from untreated adult heterozygous and DNA-PKcs null mice displayed comparable cytoarchitecture and undetectable levels of cell death.

  • MedlinePlus Health Information. consumer health - Seizures.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TOLUENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16216017.001).
  • [ISSN] 1050-9631
  • [Journal-full-title] Hippocampus
  • [ISO-abbreviation] Hippocampus
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS042826-03; United States / NINDS NIH HHS / NS / R01 NS042826; United States / NINDS NIH HHS / NS / R01 NS042826-03; United States / NINDS NIH HHS / NS / R01 NS4286
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzothiazoles; 0 / DNA-Binding Proteins; 0 / Excitatory Amino Acid Agonists; 0 / Nuclear Proteins; 0 / Thiazoles; 0 / Tumor Suppressor Protein p53; 0 / pifithrin; 3FPU23BG52 / Toluene; EC 2.7.11.1 / DNA-Activated Protein Kinase; EC 2.7.11.1 / Prkdc protein, mouse; SIV03811UC / Kainic Acid
  •  go-up   go-down


49. Milligan DW, Fernandes S, Dasgupta R, Davies FE, Matutes E, Fegan CD, McConkey C, Child JA, Cunningham D, Morgan GJ, Catovsky D, National Cancer Research Institute Haematological Studies Group: Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood; 2005 Jan 01;105(1):397-404
MedlinePlus Health Information. consumer health - Seniors' Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses.
  • We have assessed autologous stem cell transplantation after treatment with fludarabine in previously untreated patients with chronic lymphocytic leukemia (CLL).
  • This study is the first to enroll previously untreated patients and follow them prospectively.
  • It is of concern that 5 of 65 (8%) patients developed posttransplant acute myeloid leukemia/myelodysplastic syndrome.
  • [MeSH-major] Aging / physiology. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / surgery. Transplantation, Autologous / immunology
  • [MeSH-minor] Adult. Disease Progression. Female. Follow-Up Studies. Hematopoietic Stem Cell Mobilization. Humans. Male. Middle Aged. Myelodysplastic Syndromes / complications. Neoplasm, Residual / pathology. Pilot Projects. Survival Rate

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15117764.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0001160
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


50. Dogan EA, Usta BE, Bilgen R, Senol Y, Aktekin B: Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy. Epilepsy Behav; 2008 Jul;13(1):156-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy.
  • OBJECTIVE: The aim of the study described here was to investigate the efficacy, tolerability, and side effects of oxcarbazepine (OXC) monotherapy in newly diagnosed, previously untreated adult and elderly patients with partial epilepsy.
  • CONCLUSION: Although the limitations of our study include its open-label design, the results suggest that OXC monotherapy may be regarded as an effective first-line monotherapy option for adult and elderly patients with partial epilepsy, but has low efficacy in patients with cerebral tumors.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Drug Evaluation. Female. Humans. Male. Middle Aged. Prospective Studies. Retrospective Studies

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • Hazardous Substances Data Bank. OXCARBAZEPINE .
  • Hazardous Substances Data Bank. CARBAMAZEPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331816.001).
  • [ISSN] 1525-5069
  • [Journal-full-title] Epilepsy & behavior : E&B
  • [ISO-abbreviation] Epilepsy Behav
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 33CM23913M / Carbamazepine; VZI5B1W380 / oxcarbazepine
  •  go-up   go-down


51. Mazziotti G, Bianchi A, Bonadonna S, Nuzzo M, Cimino V, Fusco A, De Marinis L, Giustina A: Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J Bone Miner Res; 2006 Apr;21(4):520-8
MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy.
  • This cross-sectional study shows that a high number of untreated adult patients with GHD develop radiological vertebral deformities.
  • MATERIALS AND METHODS: One hundred seven adult hypopituitary patients (67 males and 40 females; mean age, 47 years; range: 16-81 years) with severe GHD and 130 control subjects (39 males, 91 females; mean age: 58.9 years; range: 26-82 years) were evaluated for BMD (DXA) and vertebral deformities (quantitative morphometric analysis).
  • The fracture prevalence, as well as the fracture number, was significantly higher in untreated versus treated patients (78.6% versus 53.8%; chi2: 6.7; p = 0.009), although the two groups of patients did not show any significant difference in median T score.
  • In untreated GHD patients, the prevalence of vertebral deformities was correlated with T score (p = 0.002) and duration of disease (p = 0.003).
  • CONCLUSIONS: This cross-sectional study reports high prevalence of vertebral radiological deformities in adult patients with untreated GHD.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bone Density / physiology. Cross-Sectional Studies. Female. Fractures, Bone / epidemiology. Humans. Male. Middle Aged. Prevalence. Risk Factors

  • Genetic Alliance. consumer health - Spinal Deformities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16598371.001).
  • [ISSN] 0884-0431
  • [Journal-full-title] Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • [ISO-abbreviation] J. Bone Miner. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


52. Rödel S, Engert A, Diehl V, Reiser M: Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malignant non-Hodgkin's lymphomas: long-term follow-up of a pilot study. Leuk Lymphoma; 2005 Dec;46(12):1729-34
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Untreated adult patients with aggressive NHL, presenting with Ann Arbour stage II-IV disease or stage I with bulky disease, and with at least one of the following risk factors: age > 60 years, advanced disease, elevated serum lactate dehydrogenase level, Eastern Cooperative Oncology Group (ECOG) performance status >or= 2, presence of extranodal sites of disease and bulky disease, were treated with the ACOMED regimen consisting of 4-6 cycles of adriamycin 25 mg/m(2) i.v. on days 4-5, cyclophosphamide 250 mg/m(2) i.v. on days 1-5, vincristine 2 mg i.v. absolute on day 1, methotrexate 500 mg/m(2) i.v. on day 1 with leucovorin-rescue after 24 h 30 mg/m(2) i.v. and 3 x 15 mg p.o., etoposide 100 mg/m(2) i.v. on days 3-5, dexamethasone 10 mg/m(2) p.o. on days 1-5 and granulocyte colony-stimulating factor support, repeated on day 21.
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Radiotherapy / adverse effects. Survival Analysis. Survivors. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353313.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


53. Cronin JG, Mesher D, Purdie K, Evans H, Breuer J, Harwood CA, McGregor JM, Proby CM: Beta-papillomaviruses and psoriasis: an intra-patient comparison of human papillomavirus carriage in skin and hair. Br J Dermatol; 2008 Jul;159(1):113-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Plucked eyebrow hairs and forearm skin scrapes were collected from 20 newly diagnosed, previously untreated adult patients with psoriasis and 23 normal controls.
  • [MeSH-minor] Adult. Aged. Case-Control Studies. DNA, Viral / genetics. Eyebrows / metabolism. Female. Genotype. Humans. Male. Middle Aged. Skin / metabolism

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Hair Problems.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2000 Mar;114(3):403-7 [10692096.001]
  • [Cites] J Gen Virol. 2007 May;88(Pt 5):1489-95 [17412978.001]
  • [Cites] J Clin Microbiol. 2000 Jun;38(6):2087-96 [10834958.001]
  • [Cites] J Invest Dermatol. 2000 Jun;114(6):1148-53 [10844558.001]
  • [Cites] J Med Virol. 2000 Jul;61(3):289-97 [10861635.001]
  • [Cites] J Virol. 2000 Dec;74(24):11636-41 [11090162.001]
  • [Cites] Arch Dermatol. 2001 Feb;137(2):229-31 [11176704.001]
  • [Cites] Arch Dermatol. 2001 Mar;137(3):384 [11255361.001]
  • [Cites] J Am Acad Dermatol. 2001 Apr;44(4):681-6 [11260548.001]
  • [Cites] Int J Cancer. 2001 Mar 15;91(6):828-34 [11275987.001]
  • [Cites] Arch Dermatol. 2001 Oct;137(10):1373 [11594869.001]
  • [Cites] Arch Dermatol. 2002 May;138(5):649-54 [12020228.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):579-81 [12426567.001]
  • [Cites] J Clin Microbiol. 2003 Jun;41(6):2509-14 [12791874.001]
  • [Cites] Br J Dermatol. 2003 Oct;149(4):819-25 [14616375.001]
  • [Cites] Exp Dermatol. 2003 Dec;12(6):721-8 [14714550.001]
  • [Cites] Arch Dermatol. 2004 Mar;140(3):317-24 [15023775.001]
  • [Cites] J Clin Microbiol. 1995 Mar;33(3):690-5 [7751378.001]
  • [Cites] J Med Virol. 1995 Mar;45(3):354-60 [7775961.001]
  • [Cites] J Invest Dermatol. 1997 May;108(5):712-5 [9129220.001]
  • [Cites] J Invest Dermatol. 1998 Apr;110(4):311-7 [9540967.001]
  • [Cites] J Invest Dermatol. 1998 Apr;110(4):459-60 [9540994.001]
  • [Cites] J Invest Dermatol. 1998 Jul;111(1):123-7 [9665398.001]
  • [Cites] J Invest Dermatol. 1998 Sep;111(3):541-2 [9740257.001]
  • [Cites] J Invest Dermatol. 1999 Mar;112(3):259-63 [10084299.001]
  • [Cites] J Invest Dermatol. 1999 Jul;113(1):122-6 [10417630.001]
  • [Cites] Br J Dermatol. 1999 Aug;141(2):246-9 [10468795.001]
  • [Cites] Immunol Today. 1999 Oct;20(10):475-6 [10500318.001]
  • [Cites] J Clin Microbiol. 1999 Nov;37(11):3545-55 [10523550.001]
  • [Cites] Clin Microbiol Infect. 2005 Jan;11(1):47-51 [15649303.001]
  • [Cites] Exp Dermatol. 2005 Nov;14(11):824-9 [16232304.001]
  • [Cites] Semin Immunol. 2006 Dec;18(6):362-74 [17011789.001]
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):118-21 [10728604.001]
  • (PMID = 18510676.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6695
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2493061; NLM/ UKMS1917
  •  go-up   go-down


54. Arce J, Angerri O, Caffaratti J, Garat JM, Villavicencio H: Efficiency of endoscopic treatment for vesico-ureteric reflux in adults. BJU Int; 2009 Jan;103(1):71-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main indication for treatment was a history of repeated episodes of acute pyelonephritis (61%).
  • CONCLUSIONS: The endoscopic management of VUR in previously untreated adult patients is a simple and efficient technique, with low comorbidity.
  • [MeSH-minor] Adult. Female. Humans. Male. Postoperative Complications / etiology. Retrospective Studies. Secondary Prevention. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19007362.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


55. Dhanwal DK, Vyas A, Sharma A, Saxena A: Hypothalamic pituitary abnormalities in tubercular meningitis at the time of diagnosis. Pituitary; 2010 Dec;13(4):304-10
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This prospective study included 75 untreated adult patients with TBM diagnosed as "definite", "highly probable" and "probable" TBM by Ahuja's criteria and in clinical stage 1, 2 or 3 at the time of presentation to hospital.
  • [MeSH-minor] Adolescent. Adult. Female. Follicle Stimulating Hormone / blood. Humans. Hydrocortisone / blood. Luteinizing Hormone / blood. Magnetic Resonance Imaging. Male. Prolactin / blood. Thyrotropin / blood. Thyroxine / blood. Triiodothyronine / blood. Young Adult

  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495961.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 06LU7C9H1V / Triiodothyronine; 9002-62-4 / Prolactin; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; 9002-71-5 / Thyrotropin; Q51BO43MG4 / Thyroxine; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


56. Danielsson AJ, Hasserius R, Ohlin A, Nachemson AL: Health-related quality of life in untreated versus brace-treated patients with adolescent idiopathic scoliosis: a long-term follow-up. Spine (Phila Pa 1976); 2010 Jan 15;35(2):199-205
MedlinePlus Health Information. consumer health - Scoliosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life in untreated versus brace-treated patients with adolescent idiopathic scoliosis: a long-term follow-up.
  • SUMMARY OF BACKGROUND DATA: Quality of life as measured by the SRS-22 has not previously been presented for adult untreated AIS patients.
  • [MeSH-minor] Activities of Daily Living. Adolescent. Adult. Female. Follow-Up Studies. Health Surveys. Humans. Severity of Illness Index. Spine / radiography. Statistics, Nonparametric. Surveys and Questionnaires. Sweden. Treatment Outcome

  • Genetic Alliance. consumer health - Idiopathic adolescent scoliosis.
  • Genetic Alliance. consumer health - Scoliosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038869.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Tageja N, Mohammad M, Bentley G, Bishop C: Adult T-Cell Leukemia/Lymphoma with CLL-Like Morphology-A Case Report. Case Rep Med; 2010;2010:729790

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-Cell Leukemia/Lymphoma with CLL-Like Morphology-A Case Report.
  • Adult T-cell Leukemia/Lymphoma (ATL) is rarely seen in the U.S. and Europe, usually limited to African Americans from the southeastern U.S. and immigrants from HTLV-1 endemic areas.
  • We present a case of chronic adult T-cell leukemia (ATL) with Chronic Lymphocytic Leukemia- (CLL-) like morphology that remained untreated for ten years and then developed treatment refractory acute ATL crisis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1994 Feb;86(2):383-5 [8199030.001]
  • [Cites] Br J Haematol. 1999 May;105(2):369-75 [10233406.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1373-7 [18042693.001]
  • [Cites] Leuk Lymphoma. 1993 Dec;12(1-2):123-30 [8161929.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] J Clin Pathol. 1989 Jun;42(6):567-84 [2738163.001]
  • [Cites] Eur J Haematol. 2008 Mar;80(3):185-96 [18081707.001]
  • (PMID = 20368783.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2846349
  •  go-up   go-down


58. Zucchini S, Pirazzoli P, Baronio F, Gennari M, Bal MO, Balsamo A, Gualandi S, Cicognani A: Effect on adult height of pubertal growth hormone retesting and withdrawal of therapy in patients with previously diagnosed growth hormone deficiency. J Clin Endocrinol Metab; 2006 Nov;91(11):4271-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect on adult height of pubertal growth hormone retesting and withdrawal of therapy in patients with previously diagnosed growth hormone deficiency.
  • CONTEXT: GH replacement therapy in GH-deficient (GHD) patients is usually continued until adult height despite the fact that most of these subjects display a normal secretion when retested at the end of growth.
  • MAIN OUTCOME MEASURES: Percentage and characteristics of normalized subjects at retesting, outcome of treatment in the subjects treated or untreated to adult height, and factors predictive of growth outcome were measured.
  • Mean adult height was 165.1 +/- 4.5 cm in the male group treated until adult height vs. 164.0 +/- 3.4 cm in the group who suspended therapy at retesting.
  • Mean adult height was 153.2 +/- 4.1 cm in the female group treated until adult height vs. 152.9 +/- 5.2 cm in the group that suspended therapy at retesting.
  • As regards the parameters expressing the final outcome, the only difference was found in the mean increment adult height-target height sd score in favor of the male group treated until adult height.
  • In both sexes, therapy duration and GH levels at diagnosis and at retesting were unrelated to adult height parameters and to height increments during the period of observation.
  • The withdrawal of GH therapy in these subjects after retesting was not associated with a catch down growth, and they obtained an adult height similar to those obtained by the GHD subjects treated until adult height.

  • Genetic Alliance. consumer health - Adult Growth Hormone Deficiency.
  • Genetic Alliance. consumer health - Growth Hormone Deficiency.
  • MedlinePlus Health Information. consumer health - Puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912138.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones; 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


59. Wiśniewski A, Milde K, Stupnicki R: [Spontaneous growth of girls with Turner's syndrome until 6 years of age]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006;12(1):7-11
MedlinePlus Health Information. consumer health - Turner Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A marked short stature is a prime symptom of the disease, the average adult body height of untreated women being by 23 cm lower than that of healthy ones.
  • At the age of 6 years, the average difference in body height between Turner and healthy girls exceeds 1/3 of the final growth deficit noted in untreated adult women with TS.

  • MedlinePlus Health Information. consumer health - Developmental Disabilities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16704855.001).
  • [ISSN] 1234-625X
  • [Journal-full-title] Endokrynologia, diabetologia i choroby przemiany materii wieku rozwojowego : organ Polskiego Towarzystwa Endokrynologów Dziecięcych
  • [ISO-abbreviation] Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


60. Slotte C, Lundgren D, Sennerby L: Bone morphology and vascularization of untreated and guided bone augmentation-treated rabbit calvaria: evaluation of an augmentation model. Clin Oral Implants Res; 2005 Apr;16(2):228-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone morphology and vascularization of untreated and guided bone augmentation-treated rabbit calvaria: evaluation of an augmentation model.
  • To our knowledge, however, few studies on the characteristics of the untreated calvaria regarding bone density, vessel topography, and their intra/interindividual variations and associations are available.
  • The aims of this investigation were to (1) map the large vessel topography of the skull vault, (2) describe the parietal bones of the adult rabbit histologically and morphometrically, and (3) histologically compare untreated parietal bone with parietal bone that had been treated with a GBA device.
  • MATERIAL AND METHODS: Ten adult untreated rabbits were microangiographed.
  • In addition, sections from 14 GBA-treated rabbit skulls (of the same race, sex and age as the untreated animals) served as reference specimens for comparison.
  • Hollow connections were frequently found in both the outer and inner cortical plates in both the untreated and the GBA-treated specimens.
  • The morphometric measurements revealed similar proportions of cortical, trabecular, and marrow areas in the right and left untreated bones.
  • Bone density was similar in the right and left untreated and GBA-treated specimens, as was the frequency and width of hollow connections through the cortical bone plates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15777333.001).
  • [ISSN] 0905-7161
  • [Journal-full-title] Clinical oral implants research
  • [ISO-abbreviation] Clin Oral Implants Res
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


61. Ramos Costa Mdo R, de Oliveira MA, Caetano LB, Santoro IL, Godoy Fernandes AL: Time required to achieve asthma control in not previously inhaled corticosteroid treated adult patients. J Asthma; 2008 Sep;45(7):579-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time required to achieve asthma control in not previously inhaled corticosteroid treated adult patients.
  • METHODS: This 5-month clinical trial enrolled previously untreated adult asthma patients at the Asthma Center of the President Dutra Public Hospital/Federal University of Maranhao-Brazil.
  • [MeSH-minor] Administration, Inhalation. Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Time Factors


62. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood; 2008 Feb 1;111(3):1060-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a histone deacetylase inhibitor active clinically in cutaneous T-cell lymphoma and preclinically in leukemia.
  • Patients with relapsed or refractory leukemias or myelodysplastic syndromes (MDS) and untreated patients who were not candidates for chemotherapy were eligible.
  • Of 41 patients, 31 had acute myeloid leukemia (AML), 4 chronic lymphocytic leukemia, 3 MDS, 2 acute lymphoblastic leukemia, and 1 chronic myelocytic leukemia.
  • [MeSH-major] Enzyme Inhibitors / therapeutic use. Histone Deacetylase Inhibitors. Hydroxamic Acids / therapeutic use. Leukemia / drug therapy. Leukemia / pathology. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / pathology
  • [MeSH-minor] Acetylation. Adolescent. Adult. Aged. Aged, 80 and over. Clinical Trials, Phase I as Topic. Dose-Response Relationship, Drug. Drug Tolerance. Drug-Related Side Effects and Adverse Reactions. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Histone Deacetylases / metabolism. Histones / metabolism. Humans. Male. Middle Aged. Neoplasm Staging


63. Leubner KD, Chop WM Jr, Ewigman B, Loven B, Park MK: Clinical inquiries. What is the risk of bowel strangulation in an adult with an untreated inguinal hernia? J Fam Pract; 2007 Dec;56(12):1039-41
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical inquiries. What is the risk of bowel strangulation in an adult with an untreated inguinal hernia?
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Humans. Middle Aged. Patient Selection. Practice Guidelines as Topic. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053445.001).
  • [ISSN] 1533-7294
  • [Journal-full-title] The Journal of family practice
  • [ISO-abbreviation] J Fam Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down






Advertisement